Published in Blood on July 15, 2004
MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood (2005) 4.79
Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol (2008) 4.41
Beta-thalassemia. Orphanet J Rare Dis (2010) 3.06
Principles, techniques, and applications of T2*-based MR imaging and its special applications. Radiographics (2009) 2.33
Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 2.28
Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation (2005) 2.21
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood (2012) 2.18
Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging (2006) 2.09
R2* magnetic resonance imaging of the liver in patients with iron overload. Blood (2009) 2.05
MRI detects myocardial iron in the human heart. Magn Reson Med (2006) 1.90
Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol (2007) 1.85
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw (2011) 1.85
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood (2009) 1.83
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood (2006) 1.81
Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood (2013) 1.72
Diffusion-weighted magnetic resonance imaging for staging liver fibrosis is less reliable in the presence of fat and iron. Eur Radiol (2012) 1.59
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood (2014) 1.54
Ferritin for the clinician. Blood Rev (2008) 1.46
R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging (2007) 1.38
Cardiac iron across different transfusion-dependent diseases. Blood Rev (2008) 1.37
Magnetic resonance imaging quantification of liver iron. Magn Reson Imaging Clin N Am (2010) 1.37
ISMRM workshop on fat-water separation: insights, applications and progress in MRI. Magn Reson Med (2012) 1.35
Towards explaining "unexplained hyperferritinemia". Haematologica (2009) 1.33
Fast and tissue-optimized mapping of magnetic susceptibility and T2* with multi-echo and multi-shot spirals. Neuroimage (2011) 1.25
Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin (2008) 1.23
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica (2011) 1.23
Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology (2012) 1.23
Mechanisms of tissue-iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med (2005) 1.22
Liver iron content determination by magnetic resonance imaging. World J Gastroenterol (2010) 1.21
Breathhold multiecho fast spin-echo pulse sequence for accurate R2 measurement in the heart and liver. Magn Reson Med (2009) 1.15
Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag (2007) 1.14
Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson (2014) 1.13
Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw (2013) 1.12
MRI evaluation of tissue iron burden in patients with beta-thalassaemia major. Pediatr Radiol (2007) 1.12
Myocardial T2 quantitation in patients with iron overload at 3 Tesla. J Magn Reson Imaging (2009) 1.10
Diagnosis and management of transfusion iron overload: the role of imaging. Am J Hematol (2007) 1.10
Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model. Magn Reson Med (2010) 1.09
Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major. J Magn Reson Imaging (2009) 1.09
Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One (2011) 1.08
Parametric exploration of the liver by magnetic resonance methods. Eur Radiol (2009) 1.05
Comparison of whole liver and small region-of-interest measurements of MRI liver R2* in children with iron overload. Pediatr Radiol (2010) 1.05
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica (2010) 1.04
Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol (2013) 1.03
Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.03
Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. Magn Reson Med (2013) 1.01
Normal iron metabolism and the pathophysiology of iron overload disorders. Clin Biochem Rev (2006) 0.99
Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haematol (2011) 0.99
Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol (2009) 0.99
The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages. Br J Haematol (2013) 0.99
Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood (2012) 0.98
A Room Temperature Ultrasensitive Magnetoelectric Susceptometer for Quantitative Tissue Iron Detection. Sci Rep (2016) 0.98
Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis. Wien Klin Wochenschr (2006) 0.97
The pancreas in beta-thalassemia major: MR imaging features and correlation with iron stores and glucose disturbances. Eur Radiol (2006) 0.97
Quantification of iron concentration in the liver by MRI. Insights Imaging (2011) 0.96
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol (2013) 0.95
Separate MRI quantification of dispersed (ferritin-like) and aggregated (hemosiderin-like) storage iron. Magn Reson Med (2010) 0.94
Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Reson Imaging (2014) 0.94
Liver, bone marrow, pancreas and pituitary gland iron overload in young and adult thalassemic patients: a T2 relaxometry study. Eur Radiol (2007) 0.93
Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy. Eur J Haematol (2008) 0.92
Pathophysiology and Clinical Manifestations of the β-Thalassemias. Cold Spring Harb Perspect Med (2012) 0.92
Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant (2014) 0.91
Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. Int J Hematol (2008) 0.90
Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med (2011) 0.90
High field magnetic resonance microscopy of the human hippocampus in Alzheimer's disease: quantitative imaging and correlation with iron. Neuroimage (2011) 0.89
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson (2013) 0.89
Calibration of myocardial T2 and T1 against iron concentration. J Cardiovasc Magn Reson (2014) 0.88
Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One (2013) 0.88
Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait. Blood (2014) 0.87
The global burden of iron overload. Hepatol Int (2009) 0.87
Hereditary hemochromatosis in the post-HFE era. Hepatology (2008) 0.87
Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart. Magn Reson Med (2008) 0.86
The impact of preparation and support procedures for children with sickle cell disease undergoing MRI. Pediatr Radiol (2012) 0.85
Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radic Biol Med (2014) 0.85
Multi-compartment T2 relaxometry using a spatially constrained multi-Gaussian model. PLoS One (2014) 0.84
Evaluation of MR imaging with T1 and T2* mapping for the determination of hepatic iron overload. Eur Radiol (2012) 0.84
Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol (2010) 0.83
Does fat suppression via chemically selective saturation affect R2*-MRI for transfusional iron overload assessment? A clinical evaluation at 1.5T and 3T. Magn Reson Med (2015) 0.83
Automated two-point dixon screening for the evaluation of hepatic steatosis and siderosis: comparison with R2-relaxometry and chemical shift-based sequences. Eur Radiol (2014) 0.83
Newer CT applications and their alternatives: what is appropriate in children? Pediatr Radiol (2011) 0.83
Recent advances in β-thalassemias. Pediatr Rep (2011) 0.82
Use of magnetic resonance imaging to monitor iron overload. Hematol Oncol Clin North Am (2014) 0.82
Magnetic susceptibility as a B0 field strength independent MRI biomarker of liver iron overload. Magn Reson Med (2013) 0.81
A child with hyperferritinemia: case report. Ital J Pediatr (2011) 0.81
Fast approximation to pixelwise relaxivity maps: validation in iron overloaded subjects. Magn Reson Imaging (2013) 0.81
Limitations of using logarithmic transformation and linear fitting to estimate relaxation rates in iron-loaded liver. Pediatr Radiol (2011) 0.81
Repeatability of magnetic resonance fingerprinting T1 and T2 estimates assessed using the ISMRM/NIST MRI system phantom. Magn Reson Med (2016) 0.81
Clinical penetrance of C282Y homozygous HFE haemochromatosis. Clin Biochem Rev (2004) 0.81
Estimating tissue iron burden: current status and future prospects. Br J Haematol (2015) 0.81
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. Eur J Haematol (2014) 0.80
Trends in transfusion burden among long-term survivors of childhood hematological malignancies. Leuk Lymphoma (2012) 0.79
Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia. J Magn Reson Imaging (2011) 0.79
Quantification of hepatic iron concentration in chronic viral hepatitis: usefulness of T2-weighted single-shot spin-echo echo-planar MR imaging. PLoS One (2012) 0.79
Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area. Orphanet J Rare Dis (2013) 0.79
Myocardial and hepatic T2* magnetic resonance evaluation in ex-thalassemic patients after bone-marrow transplantation. Int J Cardiovasc Imaging (2007) 0.79
Effect of inversion recovery fat suppression on hepatic R2* quantitation in transfusional siderosis. AJR Am J Roentgenol (2015) 0.79
[Individualized management and therapy of myelodysplastic syndromes]. Wien Klin Wochenschr (2008) 0.78
Measurement of liver iron concentration by MRI is reproducible. Biomed Res Int (2015) 0.78
Management of elevated serum ferritin levels. Gastroenterol Hepatol (N Y) (2008) 0.78
Guidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort. J Pediatr Hematol Oncol (2015) 0.78
Iron and noncontrast magnetic resonance T2* as a marker of intraplaque iron in human atherosclerosis. J Vasc Surg (2014) 0.78
Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med (2008) 5.43
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J Clin Invest (2003) 2.81
Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology (2010) 2.23
NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol (2009) 2.19
Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. Hepatology (2004) 2.17
The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology (2015) 2.04
Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr (2014) 2.00
Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology (2011) 1.94
Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood (2003) 1.93
Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust (2010) 1.78
The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology (2008) 1.78
HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology (2010) 1.76
The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am J Gastroenterol (2013) 1.71
Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol (2004) 1.63
Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. Ann Thorac Surg (2008) 1.59
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology (2009) 1.54
Hepatic iron loading in mice increases cholesterol biosynthesis. Hepatology (2010) 1.53
Oval cell-mediated liver regeneration: Role of cytokines and growth factors. J Gastroenterol Hepatol (2003) 1.51
Noncitrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin Proc (2008) 1.49
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology (2007) 1.49
Making sense of differing bowel cancer screening guidelines. Med J Aust (2009) 1.47
Screening for coeliac disease using anti-tissue transglutaminase antibody assays, and prevalence of the disease in an Australian community. Med J Aust (2009) 1.46
Waiting times for colonoscopy and colorectal cancer diagnosis. Med J Aust (2007) 1.45
Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology (2009) 1.44
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic. Med J Aust (2008) 1.42
Translating research to practice: bringing emergency nursing research full circle to the bedside. J Emerg Nurs (2013) 1.40
Screening sigmoidoscopy for colorectal cancer: further pieces in the jigsaw. Med J Aust (2004) 1.39
Hereditary haemochromatosis: to screen or not to screen? J Hepatol (2005) 1.38
Single spin-echo proton transverse relaxometry of iron-loaded liver. NMR Biomed (2004) 1.36
A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology (2002) 1.26
Isolation, culture and immortalisation of hepatic oval cells from adult mice fed a choline-deficient, ethionine-supplemented diet. Int J Biochem Cell Biol (2007) 1.23
The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci (2007) 1.21
Nontransferrin-bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis. Blood (2004) 1.15
Interferon-gamma exacerbates liver damage, the hepatic progenitor cell response and fibrosis in a mouse model of chronic liver injury. J Hepatol (2007) 1.12
Bi-exponential proton transverse relaxation rate (R2) image analysis using RF field intensity-weighted spin density projection: potential for R2 measurement of iron-loaded liver. Magn Reson Imaging (2003) 1.11
Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol (2003) 1.09
Attenuated liver progenitor (oval) cell and fibrogenic responses to the choline deficient, ethionine supplemented diet in the BALB/c inbred strain of mice. J Hepatol (2006) 1.08
Liver inflammation and cytokine production, but not acute phase protein synthesis, accompany the adult liver progenitor (oval) cell response to chronic liver injury. Immunol Cell Biol (2005) 1.08
HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology (2009) 1.07
Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells (2008) 1.07
Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome. Liver Int (2013) 1.05
Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health (2007) 1.05
SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway. Hum Mol Genet (2009) 1.05
Measurement and mapping of liver iron concentrations using magnetic resonance imaging. Ann N Y Acad Sci (2005) 1.04
Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. Hepatology (2006) 1.03
C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. Gastroenterology (2008) 1.03
Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.03
Mutations in the gene encoding the PML nuclear body protein Sp110 are associated with immunodeficiency and hepatic veno-occlusive disease. Nat Genet (2006) 1.03
Assessing liver fibrosis with serum marker models. Clin Biochem Rev (2007) 1.02
The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol (2015) 1.02
Impact on learning of an e-learning module on leukaemia: a randomised controlled trial. BMC Med Educ (2012) 1.01
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2011) 1.01
A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis. Br J Haematol (2009) 1.00
Pulmonary pathology in thyroid transcription factor-1 deficiency syndrome. Am J Respir Crit Care Med (2010) 1.00
Claudin-5 controls intercellular barriers of human dermal microvascular but not human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol (2013) 0.99
Differential acquisition of antigenic peptides by Hsp70 and Hsc70 under oxidative conditions. J Biol Chem (2002) 0.99
Normal iron metabolism and the pathophysiology of iron overload disorders. Clin Biochem Rev (2006) 0.99
Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents. Hepatology (2013) 0.98
Lymphotoxin-beta receptor signaling regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury. Hepatology (2009) 0.97
Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection. J Med Virol (2002) 0.97
Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proc Natl Acad Sci U S A (2012) 0.97
Chylous ascites caused by portal vein thrombosis treated with octreotide. J Gastroenterol Hepatol (2003) 0.96
Disruption of hemochromatosis protein and transferrin receptor 2 causes iron-induced liver injury in mice. Hepatology (2012) 0.96
Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumption. J Gastroenterol Hepatol (2008) 0.95
Jekyll and Hyde: evolving perspectives on the function and potential of the adult liver progenitor (oval) cell. Bioessays (2005) 0.95
Differential effects of gadolinium chloride on Kupffer cells in vivo and in vitro. Int J Biochem Cell Biol (2004) 0.95
Hepatic oval cell response to the choline-deficient, ethionine supplemented model of murine liver injury is attenuated by the administration of a cyclo-oxygenase 2 inhibitor. Carcinogenesis (2006) 0.93
Iron uptake from plasma transferrin by the duodenum is impaired in the Hfe knockout mouse. Proc Natl Acad Sci U S A (2002) 0.93
The inaccuracy of cystatin C and creatinine-based equations in predicting GFR in orthotopic liver transplant recipients. Nephrol Dial Transplant (2009) 0.92
Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta. Carcinogenesis (2005) 0.91
The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells. Am J Physiol Cell Physiol (2009) 0.91
Iron: an emerging factor in colorectal carcinogenesis. World J Gastroenterol (2010) 0.90
Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. J Gastroenterol Hepatol (2014) 0.90
Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Int J Cancer (2009) 0.89
Iron overload. Clin Chim Acta (2005) 0.89
HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology (2010) 0.89
Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease. Hepatology (2013) 0.89
Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth. Exp Hematol (2010) 0.88
Outcomes after 10 years of a community-based flexible sigmoidoscopy screening program for colorectal carcinoma. Med J Aust (2007) 0.87
A comparison of self-reported and record-linked blood donation history in an Australian cohort. Transfusion (2011) 0.87
Association between bone mineral density and erythropoiesis in Thai children and adolescents with thalassemia syndromes. J Bone Miner Metab (2006) 0.87
Mapping iron in human heart tissue with synchrotron x-ray fluorescence microscopy and cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2014) 0.86
Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity. J Gastroenterol Hepatol (2012) 0.85
Long-term mortality risks associated with mild anaemia in older persons: the Busselton Health Study. Age Ageing (2012) 0.85
HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology (2008) 0.85
Natural history of HFE simple heterozygosity for C282Y and H63D: a prospective 12-year study. J Gastroenterol Hepatol (2015) 0.85
Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand. HPB (Oxford) (2009) 0.84
Transferrin receptor 2 mediates uptake of transferrin-bound and non-transferrin-bound iron. J Hepatol (2007) 0.84
Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton) (2010) 0.84
Natural history and management of HFE-hemochromatosis. Semin Liver Dis (2011) 0.83
CD14-positive hepatic monocytes/macrophages increase in hereditary hemochromatosis. Liver Int (2004) 0.83
Iron and hepatic carcinogenesis. Crit Rev Oncog (2013) 0.83
Brain transcriptome perturbations in the Hfe(-/-) mouse model of genetic iron loading. Brain Res (2012) 0.83
Dietary iron enhances colonic inflammation and IL-6/IL-11-Stat3 signaling promoting colonic tumor development in mice. PLoS One (2013) 0.83
Hemin: a possible cause of oxidative stress in blood circulation of beta-thalassemia/hemoglobin E disease. Free Radic Res (2003) 0.83
Differential findings for CD14-positive hepatic monocytes/macrophages in primary biliary cirrhosis, chronic hepatitis C and nonalcoholic steatohepatitis. Liver Int (2006) 0.83